Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease
Year: 2003
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Amyloid
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1971834278
